

Bernadett Szabados

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11227800/publications.pdf>

Version: 2024-02-01

21
papers

782
citations

933447

10
h-index

888059

17
g-index

22
all docs

22
docs citations

22
times ranked

1427
citing authors

#	ARTICLE	IF	CITATIONS
1	Avelumab in locally advanced or metastatic urothelial carcinoma. Expert Review of Anticancer Therapy, 2022, , .	2.4	1
2	Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. European Urology, 2022, 82, 212-222.	1.9	56
3	Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et alae™s Letter to the Editor re: Alfonso GÃ3mez de LiaÃ±o Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Antiâ€“PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269â€“76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic	1.9	0
4	Re: Roman Sosnowski, Hubert Kamecki, Steven Joniau, Jochen Walz, Zachary Klaassen, Joan Palou. Introduction of Telemedicine During the COVID-19 Pandemic: A Challenge for Now, an Opportunity for the Future. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.007 . European Urology, 2021, 79, e26-e27.	1.9	0
5	Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer. European Urology Oncology, 2021, 4, 943-947.	5.4	11
6	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. European Urology Oncology, 2021, 4, 456-463.	5.4	18
7	Clinical outcome after progressing to frontline and second-line Antiâ€“PD-1/PD-L1 in advanced urothelial cancer. European Urology, 2020, 77, 269-276.	1.9	45
8	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. European Urology, 2020, 78, 731-742.	1.9	39
9	Clinical Characteristics and Outcome for Four SARS-CoV-2-infected Cancer Patients Treated with Immune Checkpoint Inhibitors. European Urology, 2020, 78, 276-280.	1.9	20
10	Adverse effects and radiological manifestations of new immunotherapy agents. British Journal of Radiology, 2019, 92, 20180164.	2.2	14
11	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nature Medicine, 2019, 25, 1706-1714.	30.7	407
12	Cytoreductive nephrectomy in the current treatment algorithm. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987902.	3.2	13
13	Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition. European Urology Oncology, 2019, 4, 659-662.	5.4	9
14	Metastatic papillary renal cell carcinoma in the era of targeted therapy â€“ a retrospective study from three European academic centres. Acta OncolÃ³gica, 2019, 58, 306-312.	1.8	3
15	Partial Nephrectomy in pT3a Tumors Less Than 7 cm in Diameter Has a Superior Overall Survival Compared to Radical Nephrectomy. Cureus, 2019, 11, e5781.	0.5	4
16	Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. European Urology, 2018, 73, 149-152.	1.9	93
17	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. British Journal of Cancer, 2018, 119, 160-163.	6.4	39
18	Emphysematous pyelonephritis: Case report and literature overview. Urologia, 2018, 85, 123-126.	0.7	8

#	ARTICLE	IF	CITATIONS
19	Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer.. Journal of Clinical Oncology, 2017, 35, 514-514.	1.6	0
20	High responses to chemotherapy in patients with metastatic urothelial cancer (MUC) after frontline immunotherapy.. Journal of Clinical Oncology, 2017, 35, 377-377.	1.6	0
21	Survival of patients with papillary type II renal cell carcinoma treated with tyrosine-kinase inhibitors: A comparison with clear cell histologies.. Journal of Clinical Oncology, 2014, 32, 511-511.	1.6	1